ATOSSA THERAPEUTICS, INC. 8-K

What Happened Atossa Therapeutics, Inc. (ATOS) filed an 8-K on February 17, 2026 (Item 3.01) announcing that Nasdaq informed the company it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 closing bid price requirement. The company had been notified on February 21, 2025 that it was not in compliance after its common stock failed to maintain a $1.00 closing bid for 30 consecutive business days. After receiving an extension, Atossa met the Nasdaq requirement of maintaining a minimum $1.00 closing bid for at least 10 consecutive trading days as of the close of trading on February 13, 2026, and its common stock will continue to be listed on The Nasdaq Capital Market.

Key Details

• Filing date: Form 8-K filed February 17, 2026 (Item 3.01).
• Noncompliance first notified: February 21, 2025 (failure to maintain $1.00 closing bid for 30 consecutive business days).
• Compliance deadline extended: Initially until August 20, 2025; Nasdaq extended the deadline by 180 days to February 17, 2026.
• Regained compliance: Required 10 consecutive trading days at or above $1.00 met as of market close February 13, 2026.
• Signature: 8-K signed by Mark J. Daniel, Chief Financial Officer.

Why It Matters Regaining compliance avoids delisting from The Nasdaq Capital Market, preserving the company’s public listing status, liquidity, and broader access to capital markets—factors important to retail investors. There were no changes to management, financial results, or other corporate actions reported in this filing; it solely confirms continued Nasdaq listing status. Investors should continue to monitor the stock price and future SEC filings for any material developments.